Talk to us a little bit about the bottlenecks for autoimmune indications and what they might be and why.

Yeah.

I, I-- you know, again, I, I think the, you know, as, as we sort of discussed, you know, last time round in terms of, you know, the patient journey, the patient experience, I think referral and screening remain, in my mind, the most underappreciated bottleneck.

So rheumatology, neurology, nephrology have not built two decades of referral infrastructure with certified cell therapy centers that oncology has.

So I think closing that gap is a shared obligation across sponsors, CROs, such as worldwide clinical trials and referring physicians, and it requires deliberate investment in clinical education, not passive diffusion of awareness, I would say.

From a development perspective, the development I direct listeners to, because I think it's the one most likely to re-- sort of almost kind of restructure this entire bottle-bottleneck is in vivo CAR T generation.

So-- And even more specifically, the shift toward things like circular RNA as the delivery payload.

Um, looking ahead, what do you think autoimmune CAR T could teach the broader cell and gene therapy field about building therapies that are, you know, not only clinically effective, like you said, but also operationally work-workable and really genuinely patient-friendly, you know, around that real support system for the, for the pa- for the patient?